指南与共识慢性肾脏病

KDIGO 2022 慢性肾脏病合并糖尿病管理临床实践指南执行摘要:基于快速涌现新证据的更新

Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.
指南 / 共识 · Kidney Int · 2022-01-01

KDIGO 2022 慢性肾脏病合并糖尿病管理指南是对2020版的聚焦更新,更新第1章(综合照护)和第4章(2型糖尿病合并CKD的降糖治疗),第2、3、5章内容未变。指南基于系统评价与GRADE方法制定,讨论证据局限性并提出需进一步研究的方向。

要点

  • KDIGO 2022指南聚焦更新糖尿病合并CKD的综合照护与2型糖尿病合并CKD的降糖治疗两章。
  • 指南制定采用系统评价与GRADE证据分级方法。
  • 原文指出证据存在局限性并列出需额外研究的方向。

核心结论

  • KDIGO 2022慢性肾脏病合并糖尿病管理指南是对2020版的聚焦更新,更新第1章综合照护和第4章2型糖尿病合并CKD的降糖治疗。

研究设计与样本

  • 由肾脏病改善全球结局组织(KDIGO)制定,按明确的证据审查与评价流程,基于相关研究的系统评价与证据质量评价,推荐强度采用GRADE方法。

主要发现

  • 第1章综合照护和第4章2型糖尿病合并CKD的降糖治疗推荐基于新证据更新,第2章血糖监测与目标、第3章生活方式干预、第5章管理方法内容未变。

临床怎么用

  • 原文未据此给出具体推荐。

局限性

  • 原文讨论了证据的局限性。
  • 原文提出了需要额外研究的方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of the KDIGO 2020 guideline on the topic. The guideline targets a broad audience of clinicians treating people with diabetes and CKD. Topic areas for which recommendations are updated based on new evidence include Chapter 1: Comprehensive care in patients with diabetes and CKD and Chapter 4: Glucose-lowering therapies in patients with type 2 diabetes (T2D) and CKD. The content of previous chapters on Glycemic monitoring and targets in patients with diabetes and CKD (Chapter 2), Lifestyle interventions in patients with diabetes and CKD (Chapter 3), and Approaches to management of patients with diabetes and CKD (Chapter 5) has been deemed current and was not changed. This guideline update was developed according to an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendations are based on systematic reviews of relevant studies and appraisal of the quality of the evidence, and the strength of recommendations followed the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) approach. Limitations of the evidence are discussed, and areas for which additional research is needed are presented.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Rossing P, Caramori ML, Chan JCN, et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int. 2022. PMID: 36272755. doi:10.1016/j.kint.2022.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。